Twist Bioscience and Element Biosciences Partner to Transform NGS Workflows with Co-Developed Solutions

Reuters
22 May
Twist Bioscience and Element Biosciences Partner to Transform NGS Workflows with Co-Developed Solutions

Twist Bioscience Corporation has announced an expanded collaboration with Element Biosciences, Inc. to transform next-generation sequencing workflows. This partnership will offer an end-to-end solution that integrates Twist's library preparation and target enrichment capabilities with Element's AVITI sequencing platform. As part of the agreement, Twist will be the sole provider of the new Trinity library prep and target enrichment kits for Element's sequencer. The collaboration aims to enhance customer access to advanced NGS tools and streamline hybrid capture processes, supporting critical markets such as agbio, population genomics, and clinical research. Through joint commercial efforts, Twist and Element are set to improve accessibility to premium life science tools and accelerate scientific discovery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522262675) on May 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10